Vaxcyte reports Q3 net loss $103M; cash $3.27B after $1.4B follow-on

Vaxcyte, Inc.

2024-Q3 EPS reported -$2.78

Net loss of $103.1M for Q3 2024 vs $92.7M in Q3 2023.
Cash, equivalents and investments $3,273M as of Sep 30, 2024, up from $1,243M at Dec 31, 2023.
VAX-31 Phase 1/2 topline positive: met non-inferiority vs PCV20 for all 20 shared serotypes at middle/high doses.
VAX-31 selected for Phase 3 adult program; pivotal non-inferiority study initiation expected by mid-2025.
VAX-24 infant Phase 2 primary series topline data expected by end of Q1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.